Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Spence, Alexander M.; Berger, Mitchel S.; Livingston, Robert B.; Ali‐Osman, Francis; Griffin, Brian R.

doi:10.1007/bf00172671

Cited by 34 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one series of 99 highgrade glioma patients (96 of whom were pretreated), single-agent procarbazine resulted in a response rate of 28% (Rodriguez et al, 1989). Platinum compounds may also offer limited benefit with response rates ranging from 11 to 21% (Buckner et al, 1990;Yung et al, 1991;Jeremic et al, 1992;Spence et al, 1992). More recently, interesting results were obtained with the ICE regimen (ifosfamide, carboplatin and etoposide) in a series of 36 well-defined patients who were all pretreated with surgery, irradiation and nitrosourea-based chemotherapy.…”

Section: Chemotherapy For Recurrent High-grade Astrocytomasmentioning

confidence: 99%

Chemotherapy for high-grade gliomas

Galanis

Buckner²

2000

Br J Cancer

View full text Add to dashboard Cite

Section: Chemotherapy For Recurrent High-grade Astrocytomasmentioning

confidence: 99%

Chemotherapy for high-grade gliomas

Galanis

Buckner²

2000

Br J Cancer

View full text Add to dashboard Cite

“…Platinum analogues represent an efficacy second line chemotherapic agent for recurrent high grade gliomas. Intravenous administration of cisplatin demonstrated to be efficacious against recurrent gliomas previously treated with nitrosureas [18], but the drug was not well tolerated because of a variety of toxicities. Intraarterial infusion of cisplatin may be effective against high grade gliomas but it also results in a severe neurological or ophthalmological toxicity [15].…”

Section: Introductionmentioning

confidence: 99%

“…A relatively new generation of drugs are the derivate of platinum, cisplatin [18,19] and carboplatin [15], alkylating agents cycle non-specific. Platinum analogues represent an efficacy second line chemotherapic agent for recurrent high grade gliomas.…”

Section: Introductionmentioning

confidence: 99%

Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study

et al. 1996

View full text Add to dashboard Cite

The object of this study is to evaluate the efficacy of a high dose of carboplatin in 20 patients operated on for high grade glioma (Group A) compared with a matched control (Group B) treated with BCNU administered after radiotherapy. The toxicity profile has been evaluated during the therapy. The survival of patients entering this study was measured in terms of months: the mean survival time was 10.45 months and the median 11.0 months in the group treated with carboplatin (8 patients are still alive); the 18-month survival rate was 10%. The mean survival time of the control group was 9.85 months and the median 10.5 months; no patients are still alive and the 18-month survival rate was 0%. On the basis of our phase II clinical study, we could conclude that i.v. administration of high-doses of carboplatin in high grade gliomas is generally well tolerated and the results are better than those of a matched control treated with 1-2 courses of BCNU (low-dose). The adjuvant treatment and the role of carboplatin in the therapy of high grade gliomas is discussed.

show abstract

“…In 1 study, 4 of 21 patients (19%) with nitrosourea-refractory high-grade glioma achieved a partial response (PR) with acceptable toxicity after a dose of 100 mg/m 2 of cisplatin administered on Day 1 and Day 8 every 4 weeks. 10 Given the lack of overlapping dose-limiting toxicity and minimal cross-resistance, the combination of cisplatin and carmustine is potentially active in gliomas. This combination has been studied in other solid tumors, but with myelosuppression as the dose-limiting toxicity.…”

mentioning

confidence: 99%

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high‐grade glioma

Blumenthal

Rankin

Eyre

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND.The poor prognosis reported for patients with high‒grade glial neoplasms indicates a need for the development of multimodality therapeutic approaches. The addition of chemotherapy has contributed variably to increased survival. The objective of the current study (Southwest Oncology Group [SWOG] 9016) was to determine whether concurrent radiotherapy and chemotherapy with the combination of carmustine and cisplatin could be given safely in a cooperative group setting. Additional objectives included the estimation of response rate, the rate of disease stabilization, and the probability of 1‐year survival.METHODS.SWOG 9016 study included 59 eligible patients with grade III or IV astrocytoma who received radiotherapy concurrently with carmustine/cisplatin chemotherapy. Patients were required to have either measurable or evaluable disease. The therapeutic endpoints were comprised of complete response (CR), partial response (PR), or progressive disease (PD).RESULTS.Six patients achieved a CR (CR rate of 10%; 95% confidence interval [95% CI], 4–21%), 4 achieved a PR (PR rate of 7%; 95% CI, 2–16%), and 2 patients (3%) experienced an unconfirmed response. Twenty‐four patients (41%; 95% CI, 28–54%) had stable disease and 10 patients (17%) demonstrated PD. The overall disease stabilization rate (CR + PR + stable disease, excluding unconfirmed response) was 58% (95% CI, 44–70%).CONCLUSIONS.Despite the presence of a cohort of long‒term survivors, the results of the current study do not appear to support the additional studyor routine use of concurrent cisplatin and carmustine. Cancer 2008. © 2008 American Cancer Society.

show abstract

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Cited by 34 publications

References 15 publications

Chemotherapy for high-grade gliomas

Chemotherapy for high-grade gliomas

Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high‐grade glioma

Contact Info

Product

Resources

About